Activation of the complement system promotes the removal of pathogens and tissue damage products from the brain and may also be involved in neuronal cell death in neurodegenerative diseases. Here, we analyzed the expression of C1q, the initial recognition subcomponent of the classic complement cascade, in the substantia nigra pars compacta (SNc) in Parkinson disease (PD) and control cases using immunohistochemistry and in situ hybridization. Microglia were determined to be the only cells that expressed C1q in the SNc and other brain areas. In the SNc of PD cases, there was increased deposition of extracellular neuromelanin in the parenchyma, resulting from degeneration of dopaminergic neurons. Neuromelanin granules and blebs of degenerated neurons seemed to be opsonized by C1q and phagocytosed by C1q-positive microglia and macrophages in the parenchyma and in the perivascular spaces. Neuromelanin-laden C1q-positive cells were also attached to the luminal surfaces of blood vessels in the SNc in PD. Thus, we present evidence suggesting that microglia are capable of phagocytosing and clearing cellular debris of degenerating neurons from the SNc through a C1q-mediated pathway in PD.
INTRODUCTION
The complement system consists of multiple soluble and membrane-anchored proteins that are essential components of the innate immune system. A classic, an alternative, and a lectin-initiated pathway of complement activation have been identified. The classic pathway is activated by the first component C1q, a macromolecule formed by peptide chains A, B, and C (1). C1q binds a wide range of ligands including the complement fixation sites of immunoglobulins and apoptotic cells to form opsonins and chemoattractant anaphylatoxins that increase the efficiency of phagocytosis (2, 3) . Complement components and regulators are elevated in various human and animal neurodegenerative (4Y8) and neuroinflammatory conditions (9Y11). Mice deficient in classic complement activation are partly protected against spongiform encephalopathy after exposure to prion protein (12) and have attenuated oxidative brain injury (13) . On the other hand, complement activation can inversely reduce neurodegeneration and plaque formation in a mouse model of Alzheimer disease (14) and is critical for the immune response in neuroinfectious diseases (15) . Recent evidence suggests that classic complement activation is also involved in synapse elimination during development (16) . C1q can drive microglial activation (17) , which can precede bloodbrain barrier dysfunction (18) . Collectively, the available data suggest that C1q can be implicated in various ways in the pathogenesis of diverse neurodegenerative diseases.
Parkinson disease (PD) is clinically characterized by an akinetic-rigid syndrome caused by a progressive demise of neuromelanin (NM)-containing dopaminergic neurons in the substantia nigra pars compacta (SNc) (19) . Data from postmortem studies provided the first evidence for neuroinflammatory processes in PD. Activated microglial cells were found within the SNc in PD (20) . These cells were identified by their immunoreactivity for HLA-DR, a cell surface major histocompatibility complex class II molecule (21) . Functional brain scans with the microglial benzodiazepine receptor ligand PK-11195 have confirmed neuroinflammatory processes in the brains of patients with PD (22, 23) . Microglial activation is also observed in animal PD models, in which injury to the nigrostriatal pathway is induced by neurotoxins or manipulations of the genes involved in the hereditary forms of PD (24) . The pathobiologic relevance of these processes has been demonstrated by the protection of neurons in PD animal models using drugs that modify innate immune responses (25, 26) .
Only a few studies have analyzed the complement system in PD. Serum complement levels were found to be in the reference range in PD (27) . In the cerebrospinal fluid, circulating immune complexes to C1q were not different between PD and other akinetic-rigid syndromes (7) . Another study did not find any immunostaining of cortical Lewy bodies for complement factors (28) . However, in the SNc in PD (but not in controls), intraneuronal and extraneuronal Lewy bodies and dendritic spheroid bodies stained for C3d, C4d, C7, and C9, but no C1q immunoreactivity was detected (29) . In this study, we reevaluated C1q expression in the SNc in PD by in situ hybridization (ISH) and immunohistochemistry (IHC).
MATERIALS AND METHODS

Human Brain Tissue
Autopsies from PD patients (n = 5) and control subjects (n = 5) were obtained from the German Brain Net (www.brainnet.net). Control subjects died without known neurological or psychiatric deficits. The diagnosis of PD was made by movement disorders specialists of the basis of validated clinical criteria (30) and confirmed by postmortem neuropathological examination. Patients with PD and control subjects were matched with respect to sex, age at death, and interval from death to tissue fixation (Table 1) . Formalin-fixed, paraffinembedded, coronal sections (7 Km, n = 2 per brain) containing the entire cross section of the SNc at the level of the red nucleus were immunostained for C1q and quantitatively analyzed (Table 1 ). In addition, formalin-fixed, paraffin-embedded sections (7 Km thick) and formalin-fixed, sucrose-protected cryosections (14 Km thick) from the midbrain (containing the SNc), brainstem, spinal cord, basal ganglia, hippocampus, and several cortical areas from individuals without neuropsychiatric disorders (1 female and 2 male; mean age, 67 T 15.1 years at death; postmortem interval, 16.7 T 6.4 hours) from the Department of Anatomy (Philipps University, Marburg, Germany) were analyzed. These tissues were used only for extensive single and double IHC and ISH and combination of both techniques to map C1q expression within the human brain but not for the comparison of PD versus controls. All human materials used were obtained by written informed consent from legally authorized persons.
Single and Double IHC
Formalin-fixed, 7-Km-thick human tissue sections were deparaffinized and cooked for 15 minutes at 92 to 95-C in citrate buffer (pH 6.0; Sigma-Aldrich, Munich, Germany) in a pressure cooker for antigen retrieval (10) . Immunohistochemistry was carried out using biotinylated secondary antibodies from donkey (1:200; Dianova, Hamburg, Germany) and standard avidin-biotin-peroxidase techniques (1:500, Vectastain Elite ABC Kit; Boehringer, Mannheim, Germany).
Visualization was performed enzymatically by incubating with 3, 3 ¶-diaminobenzidine (DAB; Sigma-Aldrich), resulting in a brown staining, or enhanced by addition of nickel sulfate (Ni; Fluka, Buchs, Switzerland), resulting in a dark blue/black staining. Costaining of C1q with other antigens in the same tissue section was analyzed by sequential performed enzymatic double IHC, as described (10) . The first staining was visualized with DAB and Ni; the second staining was performed only with DAB. The following antibodies were used: sheep polyclonal anti-C1q (68-011, 1:3000; ICN Biochemicals, Irvine, CA), rabbit polyclonal anti-ionized calcium binding adaptor molecule (Iba1) (019-19741, 1:2000; WAKO Chemicals, Osaka, Japan), mouse monoclonal antiY2 ¶, 3 ¶-cyclic nucleotide 3 ¶-phosphodiesterase (CNPase) (AB-1, 1:500; Neomarkers, Fremont, CA), guinea pig polyclonal anti-glial fibrillary acidic protein (GFAP) (GP-52, 1:1000; Progen, Heidelberg, Germany), rabbit polyclonal anti-von Willebrand factor (vWF) (A0082, 1:1000; DAKO, Hamburg, Germany), mouse monoclonal anti-neuronal nuclei (NeuN) (MAB37, 1:500; Chemicon International, Temecula, CA), and mouse monoclonal anti-Ki67 (550609, 1:500; BD Biosciences Pharmingen, Heidelberg, Germany).
Single and Double ISH
In situ hybridization was performed using 35 S-UTPY or digoxigenin (DIG)-UTPYlabeled riboprobes complementary to human C1q A (NM015991; È0.65 kb subcloned in pBluescript KS+) and C1q C chains (NM172369; È0.45 kb subcloned in pGEM-T easy) on formalin-fixed, sucrose-protected tissue cryosections (14 Km thick) (10) . The specificity of hybridization signals was assessed by performing experiments with complementary RNA probes in sense strand orientation. For visualization of radioactive hybridization signals, sections were coated with nitroblue tetrazolium 2 nuclear emulsion (Eastman Kodak, Rochester, NY) and stored at 4-C. After 2 to 3 weeks of exposure, slides were developed (Kodak D19), fixed, and counterstained with hematoxylin. Visualization of nonradioactive hybridization signals was performed with alkaline phosphatase-conjugated anti-DIG Fab fragments (Boehringer), 5-bromo-4-chloro-3-indolyl phosphate, and nitroblue tetrazolium 2 salt (Boehringer). Detection of 2 different RNA transcripts in the same tissue section was performed with a combination of radioactive and nonradioactive riboprobes (10). Two sections per SNc of each PD and control subject were analyzed. Means T SEM were quantified for the control and PD groups and analyzed by Mann-Whitney U test. *p G 0.05. †Neuromelanin-positive neurons with surface-staining for C1q. n, number of individuals; n.a. not applicable; n.s., not significant; NM, neuromelanin; PD, Parkinson disease; PMD, postmortem delay (time from death to tissue fixation); SNc, substantia nigra pars compacta.
Immunofluorescence Combined With ISH
Immunohistochemistry was performed in combination with ISH on formalin-fixed, sucrose-protected cryosections to visualize antigens with an RNA transcript in the same tissue section. Hybridization with the 35 S-labeled riboprobe was performed on formalin-fixed, sucrose-protected 14-Km-thick cryosections. Before covering the slides with K5 photoemulsion (Ilford, UK) for a 3-week exposure at 4-C, immunofluorescence staining was performed with a fluorochromeconjugated secondary antibody (1:200; Dianova).
Image Analysis
An Olympus AX70 microscope (Olympus Optical, Hamburg, Germany) equipped with dark-field and bright-field illumination and different fluorescent filters were used for analysis of IHC, ISH, and immunofluorescence histochemistry. Images were captured digitally (Spot RT Slider Camera; Diagnostic Instruments, Inc., Sterling Heights, MI). Neuromelanin-positive and C1q-positive cells with clearly identified nuclei in the section plane of the SNc were analyzed to determine their number and phenotype. Inflammatory and degenerative cellular reactions were analyzed by a blinded observer and scored for each case as follows: 1, none; 2, rare; 3, moderate; and 4, frequent.
Statistics
Data are shown as mean T SEM. The Mann-Whitney U test was used to determine whether difference existed between the data of PD (n = 5) and matched control (n = 5) groups (Tables 1 and 2 ). A value of p G 0.05 was considered significant.
RESULTS
Microglial Expression of C1q in the Human Brain
We first determined that, in the normal brain, C1q protein is expressed in microglia, as evidenced by coimmunostaining with the marker Iba1 (Fig. 1A) . In situ hybridization with riboprobes against the transcripts of 2 of 3 C1q chains demonstrated that both C1q A and C1q C messenger RNA (mRNA) were expressed in microglia (Figs. 1, BYD) . Costaining of C1q with markers of other brain resident cells (GFAP for astrocytes, CNPase for oligodendrocytes, NeuN for neurons, and vWF for endothelial cells) revealed that these cells did not express C1q (not shown). The colocalization of C1q immunoreactivity with C1q mRNA confirmed that the antibody used recognized C1q protein in a sensitive and specific manner (Figs. 1E, F) . The specificity of the hybridization signals against C1q mRNA was confirmed by ISH with riboprobes in sense strand orientation, which did not show any specific signal on adjacent sections. Furthermore, in sections of human spleen and lymph node (in which C1q is expressed), macrophages and dendritic cells were also C1q-immunopositive. Immunohistochemistry with omission of the C1q antibody was negative on the brain tissue sections.
Upregulation of C1q in the SNc in PD
Sections containing the SNc of PD subjects and matched control individuals without neuropsychiatric disorders were immunostained for C1q. Dopaminergic neurons in the SNc were identified by their cytoplasmic content of NM granules. In the SNc of PD cases, the mean number of NM+ neurons was significantly reduced versus controls (Table 1 ). There was no immunostaining for C1q of NM+ neuron cytoplasm in either the controls or the PD cases (Figs. 2A, B) . The membrane of somata and proximal processes of some NM+ neurons exhibited C1q immunostaining, however (inset in Fig. 2A) . The morphology and percentage of C1q-decorated NM+ neurons were not different between controls and PD (Table 1) .
C1q+ microglia were predominantly of the resting ramified-type and were located near NM+ neurons in the SNc of controls ( Fig. 2A) . In the SNc of PD subjects, the numbers of C1q+ microglia were increased, and their morphology was more of the activated macrophage type ( Fig. 2B with inset;  Figs. 3A, B) ; they also demonstrated more proliferative activity, as evidenced by nuclear immunostaining for the mitotic marker Ki67 (Figs. 3A, C) . Quantification of these findings is shown in Table 2 .
Ingestion of Extracellular NM by C1q-Positive Cells in the SNc in PD
Extracellular NM was scattered in the SNc parenchyma of PD cases, indicating dopaminergic neuron degeneration. Many diffusely distributed NM granules were coated with C1q in the parenchyma in the SNc in these cases (Figs. 4A, B) .
This phenomenon was observed rarely in control SNc, in which there was much less extracellular NM.
In the SNc of PD cases, several clusters of amoeboid C1q+ microglia were found surrounding and probably phagocytosing degenerated neuronal debris (Figs. 3A, B) . Such C1q+ microglia clusters were also occasionally observed in the control SNc.
C1q+ microglia in the SNc of PD subjects had mostly NM granules in their cytoplasm (Fig. 2B with inset) , suggesting that C1q+ microglia phagocytosed NM. In contrast, few C1q+ microglia had NM granules in the controls.
In the SNc of PD subjects, but not of controls, C1q+ microglial cells with cytoplasmic NM granules were also found in perivascular spaces and on luminal surfaces of endothelial cells of some blood vessels (Figs. 4B, C; Table 2 ).
DISCUSSION
The major finding of this study is that C1q, a humoral component of the innate immune system, is upregulated in the SNc in PD and seems to be important for microglial clearance of extracellular NM and debris of degenerated dopaminergic neurons.
Microglial Origin of C1q in Human Brain in Health and Disease
We identified microglia as the only cells that expressed C1q in the SNc and other regions of normal human brain and in PD. Our findings are consistent with our previous studies (10, 18, 31, 32) and others (33Y36) that showed constitutive expression of C1q in monocyte-derived cells in different species in health and disease. However, several studies claim that brain resident cells other than microglia are capable of synthesizing C1q. The differences of these observations might result from the use of different antibodies, tissues, and methods (37) , in vitro versus in vivo analyses (38, 39) , genetic manipulations (40), misinterpretation of deposition artifact as signals (41, 42) , or absence of adequate control experiments. Our methodological approach with double ISH and combination of ISH with IHC on human brain sections demonstrates production of C1q by microglia, suggesting uniform, conserved regulation of C1q in the brain throughout different species in health and disease.
Role of C1q on NM+ Neurons in SNc
The absence of C1q immunostaining and C1q mRNA in the cytoplasm of NM+ neurons argues against synthesis of C1q by dopaminergic neurons. The presence of C1q on the surface of some NM+ neurons may indicate deposition of externally synthesized C1q on them. C1q may be bound in a damageassociated manner to phospholipid phosphatidylserine or putative receptors expressed on these neurons (43, 44) , but it is uncertain whether the C1q-coating of NM+ neurons indicate degeneration. It is well documented that some NM+ neurons are continuously lost throughout the entire life span in healthy individuals and that the rate of degeneration is accelerated in PD (45Y49). However, because both morphology and percentage of C1q-coated NM+ neurons in the SNc were unchanged in PD versus controls, it is uncertain whether surfacebound C1q indicates ongoing degeneration in individual neurons. Moreover, we observed similar neuronal membrane staining of C1q in other CNS regions (e.g. frontal and parietal cortices, hippocampus, basal ganglia, brainstem and spinal cord [not shown]), as we had previously demonstrated in monkey brains without any differences between control and pathological conditions (10) . The biologic significance of C1q on the membrane of neurons in health and disease remains unresolved.
Role of C1q in Removal of NM+ Neuronal Debris From the SNc
This is the first study to demonstrate coating of extracellular NM granules and debris of degenerated neurons with C1q. This phenomenon most likely represents opsonization that may promote chemoattraction and enhance uptake by phagocytes (2, 3, 50) . Consistent with this hypothesis, we observed the following: (a) the number of C1q+ microglia was increased in PD cases; (b) this increase resulted at least partially from enhanced local proliferation, indicated by nuclear Ki67 staining; (c) the morphology of most C1q+ microglia was more of macrophage type; (d ) clusters of C1q+ microglia surrounded degenerating neurons; and (e) many C1q+ microglial cells contained NM in their cytoplasm. It had been shown experimentally that injected particles as well as monocytederived cells spread to perivascular spaces and leave the brain via the blood stream in a time-dependent manner (51, 52) . In addition, we observed NM-containing C1q+ cells outside the blood-brain barrier attached to the luminal surfaces of blood vessels in the SNc in PD. In sum, our observations implicate an important role of C1q in microglial function in the SNc in PD (Fig. 5) .
Role of C1q and Innate Immunity in PD
Degeneration of dopaminergic neurons results in liberation and deposition of intracellular debris (e.g. NM or >-synuclein) in the extracellular parenchyma of the SNc. Free extracellular NM and aggregated >-synuclein in the parenchyma have potent and protracted neurotoxic and proinflammatory effects (53Y57). Consistently, a florid microglial reaction accompanies the loss of dopaminergic neurons in the SNc in PD subjects as demonstrated herein and by others (20, 21, 58) . Increases in reactive microglia were also observed in elderly, normal human SNc, and correlated with extraneuronal NM deposits (59) resulting from age-related apoptosis of dopaminergic neurons (46Y48). Autoreactive T-cell activation by >-synuclein has been shown to exacerbate the degeneration of dopaminergic neurons of SNc in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine animal model of PD (60) . Consistently, antibodies against >-synuclein have been found in patients with PD (61). Both mechanisms (i.e. overt proinflammatory microglial activation and induction of an autoimmune reaction) may induce ''bystander'' neuronal death as collateral damage (62) , which may lead to further release of cellular debris, thus promoting vicious cycle of persisting neuroinflammation/neurodegeneration in the SNc, as observed in monkeys and humans after years of intoxication with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (63, 64) . Therefore, the clearance of the proinflammatory stimuli extracellular NM, >-synuclein, and apoptotic cell debris is an important task of the innate immune system to limit collateral tissue damage and inflammation (65) . Thus, (2) by microglia, which binds to extracellular NM (3) and enhances phagocytosis (4) by microglia. NM-containing microglia can proliferate (red nucleus) and leave the brain by entering into blood vessels (5) . The endfeet of a juxtavascular astrocyte contact the vessel to build up the blood-brain barrier with endothelial cells. Panel (C) depicts a higher magnification of (B). (C) A proliferating microglial cell with a phagocytosed NM granule, an extracellular NM granule and a bound C1q molecule are shown. The hexameric macromolecule C1q is formed by 3 peptide-chains (C1q A, C1q B and C1q C). The globular part of C1q protein is the recognition-binding domain.
C1q-mediated target recognition may play an important role in the control of the local immune responses (66) .
In conclusion, our findings imply that C1q might be involved in the removal of extracellular NM and debris of degenerated dopaminergic neurons from the SNc in PD (Fig. 5) . Although the presently widely accepted view considers microglial activation in PD to be deleterious (60) , recent clinical trials demonstrated consistently that the global suppression of the innate immune system might even be harmful in human neurodegenerative diseases (67, 68) . Thus, suppression of the antigen-presenting and cytotoxic (proinflammatory) properties of microglia, but stimulation of their phagocytosing (antiinflammatory) activity, rather than global microglial inhibition, may be an optimal therapeutic goal for modulating microglial activity in neurodegenerative diseases.
